Tower View Wealth Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-42,490
Closed -$5M 183
2022
Q1
$5M Buy
42,490
+463
+1% +$51.9K 2.69% 7
2021
Q4
$5.45M Buy
42,027
+163
+0.4% +$19K 2.77% 6
2021
Q3
$4.74M Sell
41,864
-105
-0.3% -$12K 2.63% 6
2021
Q2
$4.35M Sell
41,969
-81
-0.2% -$7.63K 2.2% 15
2021
Q1
$3.52M Buy
42,050
+363
+0.9% +$30.7K 1.92% 21
2020
Q4
$3.8M Buy
41,687
+1,559
+4% +$129K 2.16% 17
2020
Q3
$3.2M Buy
40,128
+210
+0.5% +$16.4K 2.09% 19
2020
Q2
$2.76M Buy
39,918
+786
+2% +$55.9K 2.02% 22
2020
Q1
$2.46M Buy
39,132
+465
+1% +$33.5K 2.22% 19
2019
Q4
$3.01M Sell
38,667
-1,485
-4% -$116K 2.28% 14
2019
Q3
$2.94M Buy
40,152
+15
+0% +$1.05K 2.43% 11
2019
Q2
$2.47M Sell
40,137
-690
-2% -$41.7K 2.11% 20
2019
Q1
$2.6M Sell
40,827
-885
-2% -$50.5K 2.31% 16
2018
Q4
$2.13M Buy
41,712
+414
+1% +$20.9K 2.2% 19
2018
Q3
$2.4M Sell
41,298
-9,798
-19% -$479K 2.1% 16
2018
Q2
$2.48M Buy
51,096
+240
+0.5% +$11.2K 2.34% 10
2018
Q1
$2.37M Sell
50,856
-4,950
-9% -$215K 2.36% 11
2017
Q4
$2.1M Buy
+55,806
New +$2.05M 1.93% 17

Other funds holding EW

Tower View Wealth Management's EW Position: Q2 2022 in Review

Tower View Wealth Management sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 42,490 shares — an estimated $5M sold.

Tower View Wealth Management first reported a position in EW in Q4 2017 and held it in 18 quarters. The position peaked at $5.45M in Q4 2021. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Tower View Wealth Management reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
  • Tower View Wealth Management sold 42,490 Edwards Lifesciences shares in Q2 2022, an estimated $5M.
  • Tower View Wealth Management first reported a position in Edwards Lifesciences in Q4 2017 and held it in 18 quarters.
  • Tower View Wealth Management's Edwards Lifesciences position peaked at $5.45M in Q4 2021.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Tower View Wealth Management's 13F filing for Q2 2022, filed 8 Aug 2022.